PerfectSpike's profile picture. Father of 4 delightful daughters, musician, computer scientist, people lover, avid cyclist, and all the while enjoying life with a Peter Pan mentality.

Ken Green

@PerfectSpike

Father of 4 delightful daughters, musician, computer scientist, people lover, avid cyclist, and all the while enjoying life with a Peter Pan mentality.

Ken Green reposted

$RGBP $RGBPP Regen presenting at Emerging Growth Conference January 25, 2023 otcmarkets.com/stock/RGBP/new…


$RGBP $RGBPP Dec. 8 2022: Regen Biopharma referenced in dendritic and tumor cell cancer vaccines market growth report. “Dendritic cell-based anti-tumor vaccines have great potential for the treatment of cancer”. Read more: tinyurl.com/u7wyym6a

PerfectSpike's tweet image. $RGBP $RGBPP  Dec. 8 2022:   Regen Biopharma referenced in dendritic and tumor cell cancer vaccines market growth report.

“Dendritic cell-based anti-tumor vaccines have great potential for the treatment of cancer”.

Read more:  tinyurl.com/u7wyym6a

$RGBP $RGBPP Dec. 2 2022: Cell therapy market report calls out Regen Biopharma as a key player, where live T-cells are injected into a patient for the treatment of cancer and other disorders. Read more: tinyurl.com/2p96f57p

PerfectSpike's tweet image. $RGBP $RGBPP  Dec. 2 2022:   Cell therapy market report calls out Regen Biopharma as a key player, where live T-cells are injected into a patient for the treatment of cancer and other disorders.
Read more:  tinyurl.com/2p96f57p

Ken Green reposted

$RGBP Live Emerging Growth Conference on 11/30 @TheRegenBio @RegenBioPharm Register: goto.webcasts.com/starthere.jsp?… Questions for the Company? [email protected] To Present [email protected] 305-330-1985 Invites: $COSM $NUWE $TCDA $CFRX $JAGX $OTTC $ZOM $TENX

EmergingGrowthC's tweet image. $RGBP Live Emerging Growth Conference on 11/30
@TheRegenBio @RegenBioPharm

Register:
goto.webcasts.com/starthere.jsp?…

Questions for the Company?
Questions@EmergingGrowth.com

To Present
Conference@EmergingGrowth.com
305-330-1985

Invites:
$COSM $NUWE $TCDA $CFRX $JAGX $OTTC $ZOM $TENX

$RGBP $RGBPP News today Nov. 18. ProMab Biotechnologies, Inc. was contracted in Sept. 2022 to validate Regen’s shRNA NR2F6-inhibiting technology. Today Regen announced first in vitro experiments designed to accomplish this validation was successful. prnewswire.com/news-releases/…

prnewswire.com

Regen BioPharma, Inc. Progresses Its DuraCAR Therapeutic

/PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) has previously discussed initiation of a series of experiments to validate its...


$RGBP $RGBPP Nov. 10 2022 - a news article covering dendritic cell vaccines gives a mention to Regen Biopharma. I recommend reading the entire transcript. tinyurl.com/3959ray6

PerfectSpike's tweet image. $RGBP $RGBPP Nov. 10 2022 - a news article covering dendritic cell vaccines gives a mention to Regen Biopharma.  I recommend reading the entire transcript.
tinyurl.com/3959ray6

Dr. Koos: "We will know more in the coming months from our experimental work how long the road will be to get our technology fine-tuned to the point where we have a proof-of-concept drug." $RGBP $RGBPP

This post is unavailable.

Ken Green reposted

Regen BioPharma is presenting at Emerging Growth Conference $RGBP $RGBPP finance.yahoo.com/news/regen-bio…


#DuraCAR Cancer Drug. From Regen's website today 10-26-22. IND has yet to be submitted. $RGBP $RGBPP regenbiopharmainc.com/product-pipeli…

PerfectSpike's tweet image. #DuraCAR Cancer Drug.   From Regen's website today 10-26-22.  IND has yet to be submitted.  $RGBP $RGBPP
regenbiopharmainc.com/product-pipeli…

Regen's patent pending proprietary intellectual property may address issues of both tumor microenvironment and cell exhaustion, allowing CAR-T to act as an effective therapy for solid tumors as well as blood cancers. Aptly named #DuraCAR (durable) CAR-T therapy. $RGBP $RGBPP

Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. $RGBP $RGBPP #DuraCAR tinyurl.com/4rd7mru4



Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. $RGBP $RGBPP #DuraCAR tinyurl.com/4rd7mru4


$RGBP $RGBPP Oct. 26: In a press release today Regen reveals the name of its new CAR-T drug (DuraCAR). Dr. Koos believes that this drug can be an effective therapy for solid tumors as well as blood cancers using patented technology. prnewswire.com/news-releases/…

prnewswire.com

Regen BioPharma, Inc. Explores the CAR-T Therapeutic Space

/PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) has filed several patents over the last year on multiple ways to improve CAR-T...


This patent application discloses novel means of generating CAR-T cells which upon activation stimulate production of various T cell-specific compounds... which act as molecular beacons that call in all surrounding T cells and instruct them to kill the cancer cell. $RGBP $RGBPP

This post is unavailable.

$RGBP Regen prev. was issued US patent #11,090,332 (Means of generating T cell immune responses to the solid tumor antigen survivin) as well as US Patent # 11,141,471 covering NR2F6 silenced CAR-T, and plans to combine these technologies with those in a patent filed 10-5-22.

This post is unavailable.

$RGBP $RGBPP Non-solicited coverage from BioSpace 9-23-22 of Regen's latest patent application. This RNA/DNA-based approach got their attention! biospace.com/article/resear…

PerfectSpike's tweet image. $RGBP $RGBPP Non-solicited coverage from BioSpace 9-23-22 of Regen's latest patent application.   This RNA/DNA-based approach got their attention!

biospace.com/article/resear…

$RGBP $RGBPP New patent filed Sept. 19. Company Combines Existing NR2F6 and Survivin Gene Silencing Findings with Second Generation Checkpoint Inhibitor Approach "...the first combination of an immunotherapy and a gene silencing agent in a single drug." prnewswire.com/news-releases/…

prnewswire.com

Regen BioPharma, Inc. Files Patent on Paradigm Shifting RNA/DNA-Based Approach to Cancer Immunoth...

/PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today filing of a provisional patent application with the USPTO entitled...


$RGBP $RGBPP This "novel" or new approach is huge IMO. Here the approach is described in easy to understand terms never before laid out. api.quotemedia.com/supplement/new…

PerfectSpike's tweet image. $RGBP $RGBPP  This "novel" or new approach is huge IMO.  Here the approach is described in easy to understand terms never before laid out.
api.quotemedia.com/supplement/new…

Loading...

Something went wrong.


Something went wrong.